Archives
-
Lamotrigine Beyond Seizure Control: A Translational Map
2026-09-21
Lamotrigine is more than a sodium channel probe for epilepsy research. This thought-leadership analysis connects ion-channel pharmacology with serotonin signaling, cardiac translation, and CYP19-related endocrine questions while providing a practical framework for reproducible assay design.
-
PDHA1 Succinylation and α-KGA in Cholangiocarcinoma
2026-09-21
A 2025 Nature Communications study identifies PDHA1 K83 succinylation as a metabolic control point that increases α-KGA accumulation and suppresses macrophage MHC-II antigen presentation through OXGR1–MAPK signaling. The findings connect tumor metabolic reprogramming with immune escape and suggest that inhibiting this axis may improve gemcitabine–cisplatin responses in cholangiocarcinoma.
-
PDHA1 Succinylation, α-KGA, and Cholangiocarcinoma
2026-09-20
A 2025 Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic control point that drives alpha-ketoglutarate accumulation and suppresses macrophage MHC-II antigen presentation through OXGR1–MAPK signaling. The findings connect tumor metabolic flux with immune escape and provide a preclinical rationale for combining succinylation-directed intervention with gemcitabine and cisplatin.
-
MDA Assays for Ferroptosis-Driven Drug Resistance
2026-09-19
A translational framework for using malondialdehyde measurement to connect ferroptosis biology, sunitinib resistance, and assay strategy in clear cell renal cell carcinoma.
-
EZ Cap™ Firefly Luciferase mRNA Workflow Guide
2026-09-18
Build sensitive, transient reporter workflows around Cap1-capped and polyadenylated luciferase mRNA for delivery, translation, viability, and imaging studies. This guide connects practical assay design with lipid nanoparticle benchmarking inspired by a renal ischemia-reperfusion study.
-
Quinolone–Coumarin Hybrids Against Toxoplasma gondii
2026-09-18
A 2024 Acta Parasitologica study evaluated 12 quinolone–coumarin hybrids derived from fluoroquinolone antibiotics and novobiocin against Toxoplasma gondii in cell-based assays. QC1, QC3, QC6, and novobiocin showed the most favorable balance between anti-parasitic activity and host-cell safety, providing a rationale for further lead optimization rather than immediate therapeutic use.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-17
Zhao and colleagues present a standardized fresh whole-blood platform for testing how metabolic interventions reshape stimulus-specific immune responses. The protocol links controlled pattern-recognition or microbial stimulation with pathway-directed inhibition and cytokine quantification, supporting more reproducible immunometabolism and cohort studies.
-
TCAIM Regulation of OGDH in Mitochondrial Metabolism
2026-09-17
The 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and lowers its protein abundance through HSPA9 and LONP1. By connecting mitochondrial proteostasis with control of a rate-limiting TCA-cycle enzyme, the work reveals a post-translational mechanism that suppresses OGDH complex activity and reshapes carbohydrate metabolism.
-
FCCP: From Bioenergetic Stress to Translational Insight
2026-09-16
FCCP is more than an oxidative phosphorylation uncoupler. By linking mitochondrial proton-gradient dissipation with HIF signaling, cancer metabolism, and the newly described CO2-dependent communication between axons and Schwann cells, this article outlines how translational researchers can use FCCP to build more informative mechanistic experiments.
-
TCAIM, OGDH Proteolysis, and Mitochondrial Metabolism
2026-09-16
The reference study identifies TCAIM as a DNAJC co-chaperone that selectively binds the OGDH subunit of the α-ketoglutarate dehydrogenase complex and promotes its mtHSP70- and LONP1-dependent degradation. Its structural, cellular, and mouse data support a model in which mitochondrial proteostasis directly adjusts metabolic enzyme abundance, activity, and bioenergetic state.
-
Ranolazine: Mechanism and Research Workflow
2026-09-15
Ranolazine is an anti-ischemic agent that primarily inhibits the cardiac late sodium current and limits sodium-dependent calcium overload. Its metabolic profile also supports glucose oxidation enhancement and experimental studies of fatty acid oxidation, myocardial relaxation, and cardiac ischemia.
-
Ibrexafungerp Against Fluconazole-Resistant C. auris
2026-09-15
Wiederhold and colleagues evaluated ibrexafungerp against fluconazole-resistant Candida auris using susceptibility testing and a delayed-treatment neutropenic mouse model. The study found reproducible in vitro activity and improved survival and renal fungal burden outcomes with higher-dose ibrexafungerp, supporting further investigation of orally administered glucan-synthesis inhibitors.
-
Oligo-dT Membrane Design for mRNA Capture
2026-09-14
The reference study establishes design rules for improving oligo-dT affinity membranes by linking ligand density, nanoscale clustering, pore size, and mRNA dimensions. Its local-density model and super-resolution measurements show why excess ligand does not necessarily improve capture and provide practical guidance for purifying long polyadenylated transcripts.
-
Ouabain at the Vascular Translation Frontier
2026-09-14
Ouabain is more than a classical sodium-potassium pump blocker: it is a mechanistic probe for testing how ion gradients, calcium handling, and vascular reserve interact across translational models. This article connects Ouabain-based perturbation strategies with recent findings on metformin-driven endothelium-dependent hyperpolarization, while providing practical guidance for cardiovascular research, assay design, and heart failure model interpretation.
-
LY364947 for TGF-β Signaling and EMT
2026-09-13
LY364947 is a selective TGF-β type I receptor kinase inhibitor for connecting proximal Smad2 signaling to EMT, fibrosis, cancer, and retinal injury phenotypes. This workflow shows how to manage DMSO stocks, pair rapid phospho-readouts with longer EMT endpoints, and interpret pathway effects alongside the latest pancreatic cancer findings.